Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker

BACKGROUND: Many putative disease blood biomarkers discovered in genomic and proteomic studies await validation in large clinically annotated cohorts of patient samples. ELISA assays require large quantities of precious blood samples and are not high-throughput. The reverse phase protein microarray...

Descripción completa

Detalles Bibliográficos
Autores principales: Aguilar-Mahecha, Adriana, Cantin, Christiane, O'Connor-McCourt, Maureen, Nantel, Andre, Basik, Mark
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672067/
https://www.ncbi.nlm.nih.gov/pubmed/19348683
http://dx.doi.org/10.1186/1477-5956-7-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672067/
https://www.ncbi.nlm.nih.gov/pubmed/19348683
http://dx.doi.org/10.1186/1477-5956-7-15

Ejemplares similares